Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 12/20 | 1.00 |
| ▸ | LGALS9 | O00182 | 6/20 | 1.00 |
| ▸ | LGALS7; LGALS7B | P47929 | 6/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 6/20 | 1.00 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.69 |
| ▸ | HK1 | P19367 | 2/20 | 0.48 |
| ▸ | HK2 | P52789 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234119 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL2431420 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL13595414 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL22243318 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL15720125 | 1.00 | LGALS3 (1.00) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL19976150 | 0.95 | LGALS3 (0.90) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL17681081 | 0.94 | LGALS3 (0.88) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL14439460 | 0.91 | LGALS3 (0.84) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL17414604 | 0.91 | LGALS3 (0.84) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 | |
| SCHEMBL17681051 | 0.87 | LGALS3 (0.76) | LGALS3LGALS9LGALS7; LGALS7BLGALS1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | claimed |
| EP-1751171-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | FORSKARPATENT I SYD AB (SE) | 2011-09-21 | — | — | EP | claimed |
| US-7638623-B2 | Galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2009-12-29 | — | — | US | claimed |
| US-20070185039-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | GALECTO BIOTECH AB (DK) | 2017-04-06 | — | — | US | disclosed |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| EP-2919802-A1 | METHODS, COMPOSITIONS AND KITS FOR TREATING, MODULATING, OR PREVENTING OCULAR ANGIOGENESIS OR FIBROSIS IN A SUBJECT USING A GALECTIN PROTEIN INHIBITOR | Tufts University (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078655-A1 | METHODS, COMPOSITIONS AND KITS FOR TREATING, MODULATING, OR PREVENTING OCULAR ANGIOGENESIS OR FIBROSIS IN A SUBJECT USING A GALECTIN PROTEIN INHIBITOR | TUFTS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-1751171-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | FORSKARPATENT I SYD AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| US-7638623-B2 | Galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2009-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | LGALS1, LGALS2, LGALS3BP | LGALS3 4/4885LGALS9 7/4885LGALS7; LGALS7B 8/4885 |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS9 9/4885LGALS7; LGALS7B 10/4885 |
| US-20070185039-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS9 8/4885LGALS7; LGALS7B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.